Clinical trial
A Phase 2, Open-Label Study to Evaluate the Safety and Antitumor Activity of Praluzatamab Ravtansine (CX-2009) in Advanced HR-Positive/HER2-Negative Breast Cancer and of Praluzatamab Ravtansine as Monotherapy and in Combination With Pacmilimab (CX-072) in Advanced Triple-Negative Breast Cancer (CTMX-2009-002)
NCT04596150 is registered in ClinicalTrials.gov with CytomX Therapeutics as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Open-Label Study to Evaluate the Safety and Antitumor Activity of Praluzatamab Ravtansine (CX-2009) in Advanced HR-Positive/HER2-Negative Breast Cancer and of Praluzatamab Ravtansine as Monotherapy and in Combination With Pacmilimab (CX-072) in Advanced Triple-Negative Breast Cancer (CTMX-2009-002)
- Lead sponsor
- CytomX Therapeutics
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- December 29, 2020
- Completion date
- June 2, 2023
- Enrollment
- 125 (actual)
- Sites
- 42
Conditions
As the registry lists them; a condition with its own page is linked.
breast cancer, breast neoplasms, breast neoplasms, hormone receptor positive/her2 negative, breast neoplasms, triple-negative, neoplasms